Compare KGS & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KGS | PCVX |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 7.0B |
| IPO Year | 2023 | 2020 |
| Metric | KGS | PCVX |
|---|---|---|
| Price | $44.42 | $60.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 11 |
| Target Price | $79.50 | ★ $117.30 |
| AVG Volume (30 Days) | 1.7M | ★ 3.7M |
| Earning Date | 11-09-2026 | 11-13-2026 |
| Dividend Yield | ★ 4.18% | N/A |
| EPS Growth | ★ 58.93 | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.18 | N/A |
| Revenue Next Year | $14.49 | N/A |
| P/E Ratio | $62.37 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.55 | $39.87 |
| 52 Week High | $77.68 | $90.75 |
| Indicator | KGS | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 35.16 | 46.07 |
| Support Level | $43.50 | $58.85 |
| Resistance Level | $49.65 | $63.08 |
| Average True Range (ATR) | 2.37 | 2.87 |
| MACD | 0.15 | -0.55 |
| Stochastic Oscillator | 18.99 | 15.18 |
Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. The company manages its business through two operating segments: Contract Services and Other Services. Contract Services consists of operating company-owned and customer-owned compression, gas treating, and cooling infrastructure, pursuant to fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings. Maximum revenue for the company is generated from its Contract Services segment.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.